Redeye: Episurf Medical - With Focus Long-term

Redeye raises its valuation on Episurf Medical but lowers near term estimates due to the corona crisis, which has halted elective surgeries. Our medium to long term conviction is enhanced, however, as we find the company’s extensive clinical pipeline promising and its substantial recent capital injection very reassuring.

Read more and download the research update: https://bit.ly/2zJZnpJ

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/